sdü tıp fak derg Medical Journal of Süleyman Demirel University 2602-2109 Süleyman Demirel Üniversitesi Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisi Varol Ercan Şahin Mehmet Aslan S.murat Özaydın Mehmet Altınbaş Ahmet 04 21 2009 13 3 1 3 04 20 2009 Copyright © 1994, Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi 1994 Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

SüleymanDemirel Üniversitesi TIP FAKÜLTESİ DERGİSİ: 2006 Eylül; 13(3) Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisiErcan Varol, Mehmet Şahin, S Murat Aslan, Mehmet Özaydın, Ahmet Altınbaş Özet Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisi Kısa dönem, 1 aylık orlistat tedavisinin lipid profili üzerine etkisini araştırmak. Onüç obez hastada düşük kalorili diyete ilave olarak günde 3 kez 120 mg orlistat verildi. Başlangıç ve 1 ay sonraki plazma lipid düzeylerine bakıldı. Trigliserid (TG) seviyesi 169.9 ± 62.7 mg/dl den 156.6 ± 60.4 mg/dl'ye (p

 Obezite Orlistat Kolesterol Trigliserid Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB & Patel IH Retrospective population- based analysis of the dose response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 82–85. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disorder 1997; 21 (suppl.3): S12–S23 Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP et al. Randomized placebo – controlled trial of orlistat of weight loss and prevention of weight regain in obese patiants. Lancet 1998; 352; 167 – 172 Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999; 281: 235–242. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance and impaired cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000; 8: 49–61. Kelley DE, Bray GA, Pi-Sunyer. Clinical efficacy of orlistat therapy in owerweight and obese patients with insulin treated-type 2 diabetes: a 1-year randomized controlled trial . Diabetes Care 2002; 25: 1033-41. Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profili, in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Therapeutics 2003; 25: 1107-22. Muls E, Kolanowski J, Scheen E, Van Gaal L. The effects of orlistat on weight and serum lipids in obese patients with hypercholestrolemia: a randomized, double blind, placebo controlled, multicentre study. Int J Obes Relat Metab Disord 2001; 25: 1713-21 Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet ( 30 % of calories from fat) on plasma lipids, glucose and insulin in obese patients with hypercholesterolemia. Am J Cardiol 2003; 91: 961–964. Bloch KV, Salles KF, Muxfeldt ES, da Rocha Nogueria A. Orlistat in hypertensive overweight / obese patients: results of a randomized clinical trial. J Hypertens 2003; 21(11): 2159-65. van Greevenbroek MM, de Bruin TW. Chylomicron synthesis by intestinal cells in vitro and in vivo. Atherosclerosis 1998; 141(suppl 1): S9–S16. Wierzbicki AS, Reynolds TM, Crook MA. Usefulness of orlistat in the treatment of severe hypertriglyceridemia. Am J Cardiol 2002; 89: 229–31. Mittendorfer B, Ostlund RE, Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorbtion. Obes Res 2001; 9: 599-604 Hutton B, Ferguson D. Changes in body weigth and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systemic rewiew of randomized clinical trials. Am J Clin Nutr 2004; 80: 1461-8